Diabetes

Pharmacists play a key role in guiding patients on GLP-1 and dual agonist therapies, supporting safe use, managing adverse effects, and promoting long-term treatment success.

As continuous glucose monitoring becomes more common, pharmacists are essential in patient education but face barriers of time, training, and reimbursement.

Leveraging staff support, multimodal education, and policy change can make CGM counseling more sustainable in community pharmacies.

Among patients with type 2 diabetes, researchers explored how tirzepatide or semaglutide use was associated with first-time reports of optic nerve or visual pathway disorders.

Pharmacists can build confidence with CGMs through hands-on experience, continuing education, and strong support from employers, peers, and manufacturers.

Investigators found that health care costs rose despite the benefits seen with starting semaglutide for patients with and without diabetes.

Pharmacists are key to CGM education, but time, training, and reimbursement remain major barriers.

Compounding pharmacies help meet patient needs by formulating alternative versions in the face of drug shortages but are no longer allowed to compound them.

Investigators find modest improvements in body weight at week 26 for CT-868 compared with the placebo.

New research shows metformin's inconsistent neuroprotective effects against Alzheimer disease, challenging its role in diabetes management for cognitive health.

Patients with type 2 diabetes and moderate cardiovascular risk had a higher rate of major heart-related events when treated with sulfonylureas.

Study data reveal that women with low blood glucose levels before conception face higher risks of adverse pregnancy outcomes, emphasizing the need for screening and education.

In a study, investigators say that a patient’s financial health should be considered when starting treatment for type 2 diabetes.

Among patients with cirrhosis receiving diuretic therapy, researchers explore the association between SGLT-2 inhibitors and the risk of serious liver outcomes.

Researchers explored how the GLP-1 medications semaglutide and tirzepatide impact incidence rates in a variety of health-related outcomes.

The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients.

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

Patients with a single cardiometabolic disease have an approximately 48% greater risk of developing all-cause dementia than those without a cardiometabolic disease.

Researchers explored the effectiveness of telephonic insulin titration by a clinical pharmacist compared with in-office titration among patients in a medical residency clinic.

Efsitora demonstrates noninferior reductions in hemoglobin A1c and similar rates in patients with an A1c level less than 7% compared with common daily insulin.

Investigators also report that sodium-glucose cotransporter 2 inhibitors are not associated with thrombotic risk.